Loading stock data…
Eikon Therapeutics (EIKN)
$10.71-0.15 (-1.38%)
Market ClosedLast close Sep 8
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | — | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$87.34M↓ | -$83.17M | — | -$71.38M↓ | -$67.78M |
| Net Income | -$82.96M↓ | -$79.66M | — | -$68.24M↓ | -$64.92M |
Peer Comparison
JNJUNHPFE
Fundamentals
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$480.75M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-53.71%
Volume
Today's trading volume
462,104
Recent News
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
Eikon Therapeutics (NASDAQ:EIKN) outlined its development strategy for selective PARP1 inhibitors and its Werner helicase inhibitor during a discussion hosted by Cantor biotech analyst Imogen Mansfield. President, Chief Executive Officer and Board Chair Roger Perlmutter and MD Anderson Cancer Center
Is Eikon Therapeutics, Inc. (EIKN) Stock a Biotech Growth Opportunity Despite Limited Q1 Updates?
We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. Eikon Therapeutics, Inc. (NASDAQ:EIKN) is one of the best up and coming stocks on our list. TheFly reported on June 3 that BofA Securities lowered its price target for EIKN to $32 from $34 while maintaining a Buy rating on […]
Spotify upgraded, First Solar downgraded: Wall Street's top analyst calls
Spotify upgraded, First Solar downgraded: Wall Street's top analyst calls